<DOC>
	<DOCNO>NCT01998958</DOCNO>
	<brief_summary>The purpose study assess efficacy dose response intranasal esketamine ( Panel A : 28 mg , 56 mg , 84 mg Panel B : 14 mg 56 mg ) compare placebo improve depressive symptom participant treatment-resistant depression ( TRD ) .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy Intranasal Esketamine Treatment-resistant Depression</brief_title>
	<detailed_description>This 2-panel , randomize ( participant assign different treatment base chance ) , double-blind ( neither investigator participant know treatment participant receives ) , placebo-controlled ( placebo inactive substance compare drug test whether drug real effect clinical trial ) , multicenter study . Approximately 100 male female adult participant diagnose TRD participate study . For participant panel ( Panel A Panel B ) , 4 study phase : 4-week screening phase , double-blind treatment phase ( Day 1 Day 15 ) , optional open-label treatment phase ( Panel A : Day 15 74 ; Panel B : Day 15 25 ) , 8-week post-treatment ( follow-up ) phase . Depending treatment Panel , patient assign intranasal placebo intranasal esketamine 14 mg , 28 mg , 56 mg , 84 mg. Safety assessment perform throughout study . The maximum study duration participant 23 week Panel A 16 week Panel B .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Treatment-Resistant</mesh_term>
	<criteria>Participant must meet Diagnostic Statistical Manual Mental Disorders Fourth Edition Text Revised ( DSMIVTR ) diagnostic criterion Major Depressive Disorder ( MDD ) , without psychotic feature , base upon clinical assessment , confirm Mini International Neuropsychiatric Interview ( MINI ) Participant 's major depressive episode treatment response must deem `` valid '' remote independent ratersParticipant must inadequate response least 2 antidepressant , least one current episode depression ; antidepressant treatment response questionnaire ( ATRQ ) use assess antidepressant treatment response current episode ; prior medication history use determine antidepressant treatment response prior episode ( ) Have Inventory Depressive SymptomsClinician rat , 30item ( IDSC30 ) total score &gt; =34 Screening predose Day 1 Participant current DSMIVTR diagnosis bipolar related disorder , intellectual disability , cluster b personality disorder ( e.g. , borderline personality disorder , antisocial personality disorder , histrionic personality disorder , narcissistic personality disorder ) Participant current prior DSMIVTR diagnosis psychotic disorder , MDD psychosis , posttraumatic stress disorder ( PTSD ) , obsessive compulsive disorder ( OCD ) Anatomical medical condition may impede delivery absorption study medication ( e.g. , undergone facial reconstruction , rhinoplasty , significant structural functional abnormality nose upper airway ; obstruction mucosal lesion nostril nasal passage ; undergone sinus surgery previous 2 year ; sign symptom rhinitis ) Has abnormal deviate nasal septum 1 follow symptom : blockage 1 nostril , nasal congestion ( especially 1sided ) , frequent nosebleed , frequent sinus infection , time facial pain , headache , postnasal drip Has history substance abuse ( drug alcohol ) dependence ( except nicotine caffeine ) within previous 1 year screen visit Participant know allergy , hypersensitivity , intolerance , contraindication esketamine/ketamine excipients</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Treatment resistant depressive disorder</keyword>
	<keyword>Intranasal esketamine</keyword>
	<keyword>Efficacy</keyword>
	<keyword>SYNAPSE</keyword>
	<keyword>JNJ-54135419</keyword>
</DOC>